
About Selvita
Selvita is a publicly listed company based in Krakow (Poland) founded in 2007 by Boguslaw Sieczkowski. Selvita is recognized as a drug discovery and development provider. It operates on a Professional Services and Managed Services model. The company has 969 employees. Selvita has completed 2 acquisitions, including Fidelta and PozLab. Its chief executive, as recorded, is Boguslaw Sieczkowski. Its website selvita.com draws about 22 thousand monthly visits. Selvita offers products and services including Drug Discovery Services and Drug Development Services. Its focus areas include Pharmaceuticals and Drug Discovery and Development. Its legal entity is Selvita S.A.
Company details
Selvita is established as an integrated service provider in drug discovery and development, offering comprehensive solutions to support customers and projects. Services are provided across various modalities including small molecules, antibodies, and biologics. Expertise is maintained in medicinal chemistry, pharmacology, and regulatory compliance under GMP and GLP standards. Operations are focused on bridging early discovery to clinical development, covering multiple therapeutic areas with a flexible engagement model for standalone or integrated programs.
- Headquarters Krakow, Poland
- Employees 969
- Founders Boguslaw Sieczkowski
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website selvita.com
- Social LinkedIn X Facebook YouTube
- Legal Name Selvita Sa
- Annual Revenue$101.46 M (USD)6.57as on Dec 31, 2025
- Net Profit$226.31 K (USD)as on Dec 31, 2025
- EBITDA$17.19 M (USD)26.4as on Dec 31, 2025
- Latest Funding Round$5.5M (USD), Post-IPO
May 2011
- Employee Count969
- Investments & AcquisitionsFidelta
& 1 more
Products & Services of Selvita
Selvita offers a comprehensive portfolio of products and services, including Drug Discovery Services and Drug Development Services.
Comprehensive drug discovery from target to preclinical candidate.
End-to-end drug development with regulatory and analytical support.
Apps and channels of Selvita
its YouTube channel Selvita has 214 subscribers and 22 videos.
Videos from Selvita
The most watched videos on Selvita's YouTube channel, Selvita (214 subscribers). Click a video to play it here.
More on Selvita.
Funding Insights of Selvita
- Total Rounds 1
- Last Round Post-IPO — $5.5M
- First Round $5.5M
(May 2011)
All 1 funding rounds of Selvita with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2011 | $5.5M | Post-IPO | – | – | – |
People of Selvita
1 people are tracked at Selvita (1 in leadership); the tracked headcount is 969.
| Name | Role | Group |
|---|---|---|
Boguslaw Sieczkowski | Co-Founder & CEO | Leadership |
Complete people profiles for Selvita
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Selvita
Selvita is a publicly listed company on the GPW with ticker symbol SLV in Poland, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date16 Mar 2021
- Listed onWSE: SLV
- Listed entitySelvita SA
- Exchange sectorHealth technology
- ISINPLSLVCR00029
- Share price20.75 PLN (+0.24% on the day) · 2026-10-14
- Market capitalisation379,958,336.00 PLN
- EPS (diluted, trailing year)-0.11 PLN
- Volume (last session)6,793
Financials of Selvita
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 364.5M PLN | 813,000 PLN | 61.8M PLN |
| 2024 | 342.0M PLN | -6.1M PLN | 48.9M PLN |
| 2023 | 347.0M PLN | 69.9M PLN | 57.6M PLN |
| 2022 | 360.7M PLN | 30.3M PLN | 71.5M PLN |
| 2021 | 310.9M PLN | 14.9M PLN | 47.6M PLN |
Detailed financial statements for Selvita
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Selvita
Selvita has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Fidelta and PozLab.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Formulation and process development services for pharmaceuticals are provided. | pozlab.pl | Poznan, Poland | 2010 | Mar 2024 | $6.29M | |
Integrated preclinical drug discovery services are provided by Fidelta. | fidelta.eu | Zagreb, Croatia | 1952 | Nov 2020 | $36.99M |
Complete acquisition details for Selvita
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Web traffic of Selvita
The website of Selvita (selvita.com) receives about 22.5K visits a month.
- Monthly visits22.5K
▲ 103.5% vs previous month
Websites whose visitors overlap most with Selvita. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| biocentrum.com.pl | 100% | View details | |||
| criver.com | 90% | 224.6K | #186,811 | View details | |
apeiron.edu.pl | apeiron.edu.pl | 57% | #1,586,352 | – | |
| oru.se | 54% | 1.3M | #44,777 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Selvita
Complete news archive for Selvita
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Selvita
Selvita was founded in 2007 and raised its 1st funding round 4 years after it was founded.
Selvita is headquartered in Krakow, Poland. It is registered at Krakow, Lesser Poland Voivodeship, Poland.
Boguslaw Sieczkowski is the CEO of Selvita, as recorded in our data. They have also founded this company.
Selvita has 969 employees.
Annual revenue of Selvita is $101.46M as on Dec 31, 2025.
Selvita is established as an integrated service provider in drug discovery and development, offering comprehensive solutions to support customers and projects. Services are provided across various modalities including small molecules, antibodies, and biologics. Expertise is maintained in medicinal chemistry, pharmacology, and regulatory compliance under GMP and GLP standards. Operations are focused on bridging early discovery to clinical development, covering multiple therapeutic areas with a flexible engagement model for standalone or integrated programs.
Selvita offers Drug Discovery Services and Drug Development Services.
Yes, Selvita is publicly traded on GPW under the ticker symbol SLV.
Selvita operates through Selvita S.A..
